Multiple myeloma is usually diagnosed by a blood test to identify high levels of a type of protein or antibody produced by myeloma cells. The doctor also may do a bone marrow aspiration or a bone ...

Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated.

International Myeloma Foundation: “Multiple Myeloma and Anemia,” “Heart and Lung Complications.” Memorial Sloan Kettering Cancer Center: “Bone-Related Problems in Multiple Myeloma ...

Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as linked to military service in the Persian Gulf, Afghanistan and ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare. Carvykti ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead Sciences' Kite Pharma to treat relapsed or refractory multiple myeloma (RRMM). After seeing the data ...